Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 18, 2022

SELL
$177.01 - $223.45 $84,610 - $106,809
-478 Closed
0 $0
Q3 2021

Oct 18, 2021

SELL
$181.39 - $202.99 $274,805 - $307,529
-1,515 Reduced 76.02%
478 $87,000
Q2 2021

Jul 16, 2021

BUY
$187.49 - $221.1 $120,181 - $141,725
641 Added 47.41%
1,993 $402,000
Q1 2021

Apr 09, 2021

BUY
$207.02 - $241.31 $279,891 - $326,251
1,352 New
1,352 $291,000
Q4 2020

Jan 11, 2021

SELL
$207.01 - $276.09 $4,761 - $6,350
-23 Closed
0 $0
Q3 2020

Oct 23, 2020

SELL
$255.65 - $303.1 $241,333 - $286,126
-944 Reduced 97.62%
23 $6,000
Q2 2020

Jul 13, 2020

BUY
$225.48 - $295.8 $218,039 - $286,038
967 New
967 $275,000
Q1 2020

Apr 14, 2020

SELL
$199.77 - $247.81 $716,375 - $888,646
-3,586 Closed
0 $0
Q4 2019

Jan 31, 2020

BUY
$166.71 - $223.91 $582,151 - $781,893
3,492 Added 3714.89%
3,586 $785,000
Q3 2019

Oct 15, 2019

SELL
$166.23 - $187.09 $21,277 - $23,947
-128 Reduced 57.66%
94 $16,000
Q2 2019

Jul 18, 2019

SELL
$164.61 - $190.37 $93,333 - $107,939
-567 Reduced 71.86%
222 $41,000
Q1 2019

Apr 11, 2019

BUY
$163.73 - $194.7 $129,182 - $153,618
789 New
789 $146,000
Q4 2018

Jan 22, 2019

SELL
$151.91 - $192.21 $15,798 - $19,989
-104 Closed
0 $0
Q3 2018

Oct 23, 2018

BUY
$167.73 - $192.74 $16,773 - $19,274
100 Added 2500.0%
104 $20,000
Q2 2018

Aug 01, 2018

SELL
$145.72 - $169.96 $167,869 - $195,793
-1,152 Reduced 99.65%
4 $1,000
Q1 2018

May 02, 2018

BUY
$151.6 - $177.13 $166,153 - $194,134
1,096 Added 1826.67%
1,156 $184,000
Q4 2017

Feb 07, 2018

BUY
$137.28 - $155.55 $8,236 - $9,333
60
60 $9,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Nu Wave Investment Management, LLC Portfolio

Follow Nu Wave Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nu Wave Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nu Wave Investment Management, LLC with notifications on news.